Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD in Europe
Omid Seidizadeh, Research Leader of the A. Bianchi Bonomi Hemophilia and Thrombosis Center, reposted from EAHAD on LinkedIn:
”Understanding access to diagnostic tools and treatment options for von Willebrand disease across Europe is essential to improving care and identifying unmet needs.
I encourage all healthcare professionals involved in the diagnosis and treatment of VWD across Europe to take a few minutes to participate in this survey and share their experience.
Your input will help provide a clearer picture of current practice and resource availability across different clinical settings.”
Quoting European Association for Haemophilia and Allied Disorders (EAHAD)‘s post:
”The EAHAD von Willebrand Disease (VWD) Working Group has launched a new survey to assess the availability of diagnostic tools and treatment options across European medical centers.
The aim is to better understand current clinical practice, available resources, and real-world access to care across different settings.
We invite healthcare professionals to contribute their experience and insights.
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM
-
Aug 26, 2026, 13:59David McIntosh: Immunoglobulin Stewardship in the Face of Rising Demand